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A b s t r a c t  
The main objective this study is to prepare and evaluate the selfnanoemulsifying drug delivery 
(SNEDDS) system in order to achieve a better dissolution rate of a poorly water soluble drug 
valsartan.  The present research work describes a SNEDDS of valsartan using labrasol, Tween 20 
and Polyethylene glycol (PEG) 400. The pseudo-ternary phase diagrams with presence and 
absence of drug were plotted to check for the emulsification range and also to evaluate the effect of 
valsartan on the emulsification behavior of the phases. The mixtures consisting of oil (labrasol ) with 
surfactant (tween20), co-surfactant (PEG 400) were found to be optimum formulations. Prepared 
formulations were evaluated for its particle size distribution, nanoemulsifying properties, robustness 
to dilution, self emulsication time, turbidity measurement, drug content and in-vitro dissolution. The 
optimized formulations  are further evaluated for heating cooling cycle, centrifugation studies, freeze 
thaw cycling, particle size distribution and zeta potential were carried out to confirm the stability of 
the formed SNEDDS formulations. The prepared formulation has a significant improvement in terms 
of the drug solubility as compared with marketed tablet and pure drug, thus, this greater dissolution 
of valsartan from formulations could lead to higher absorption and higher oral bioavailability. 
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Over the decades, oral drug delivery system had been a very 
favourable and most explored field in pharmaceutical technology 
due to its convenience in administration. However, one of the 
limitations is that different drugs exhibit distinct and different 
delivery profile from each another. One of the most important 
factors for such phenomenon is the drugs’ solubility.  
One of the drugs struggling with solubility is Valsartan. Valsartan 
(N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl}-L-
valine) is an angiotensin II receptor blocker [1]. It is indicated for 
hypertension, heart failure and post-myocardial infarction [2]. 
According to United States Pharmacopeia, Valsartan in capsule 
form has the bioavailability of approximately 25% (range 10 – 
35%). This phenomena might be attributed to the low water 
solubility of valsartan (log P = 1.449) [3]. However, Valsartan is 
classified under Biopharmaceutical Classification System class III, 
which is a drug with low permeability, poor metabolism and high 
solubility [4]. This is because Valsartan is not entirely lipophilic and 
it exhibits pH-dependent solubility, where the solubility is 16.8 g/L 
and 0.18 g/L in phosphate buffer solution (PBS) pH 8.0 and water 
respectively. Being a weakly acidic drug (pKa = 8.15), Valsartan is 
generally in the ionized form at higher pH, and thus greater 
solubility. [4], [5] It should be noted that drugs can only cross the 
intestinal lining at its unionized and solubilised form. At the lower 
pH in the stomach, Valsartan will mainly exist in the unionized form 
which can facilitate permeation but drug solubility is the limiting 
factor. [3], [4] Therefore, it is plausible that by addressing the 
solubility issue at low pH, enhanced absorption of Valsartan and 
thus greater bioavailability can be achieved. 
Self-emulsifying drug delivery system is one of the effective 
systems in addressing solubility issues. Self-nanoemulsifying drug 
delivery system (SNEDDS) is composed of an isotropic mixture of 
oil, surfactant, co-surfactant and drug [6-7]. Upon ingestion, this 
isotropic mixture will come in contact with the aqueous phase of 
gastrointestinal tracts and form an oil-in-water emulsion at a nano-
scale range with the aid of gastrointestinal motility. This stable 
emulsion can provide a large interfacial area for partitioning of drug 
between oil and aqueous phase and potentially offer better 
dissolution rate and improved bioavailability [8].  
SNEDDS appears to be an attractive choice of formulation as it 
requires simple and cost-effective manufacturing facilities. [8] This 
is because SNEDDS is a physically stable lipid solution and it omits 
the need of high energy emulsification process, and thus reduces 
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more predictable bioavailability of SNEDDS imply the reduction in 
drug dose and possibly eliminate the dose-related side effects [9-
10]. Many of the past researches had been done on this attractive 
choice of delivery, mostly on chemical entities which are poorly 
water soluble, such as all-trans-retinol acetate [11], carvedilol [12], 
flutamide [13,14] and fenofibrate [15] showed more than 90% of 
cumulative drug release. Based on the above fact the study was 
aimed to prepare and characterize SNEDDS of poorly soluble drug 
valsartan using optimized choice and ratio of oil, surfactant and co-
surfactant to improve the rate of dissolution drug which leads to 
increase of bioavailability of drug.  
Material and Methods 
Materials 
Valsartan is purchased from Aurobindo Pharma Ltd, India. Capryol 
90, Labrafil M 1944 CS, Labrafac Lipophile WL 1349(504), 
Labrasol and Transcutol HP are gift samples from Gattefosse ®, 
France. Tween 20, Tween 40 and Tween 60 are purchased from 
R&M Chemical, UK. PEG 300, PEG 400 and PEG 600 are 
manufactured by Aldrich ®, Germany, while is purchased from 
Sigma-Aldrich chemicals, USA. Olive oil purchased from Fluka ® 
chemicals, USA. Other analytical solvent used are of analytical 
grade. The marketed product is purchased with legal prescription 
and the name is not revealed due to confidentiality.  
Solubility Studies 
The first step of this experiment design is to screen the solubility of 
poorly soluble Valsartan in each of the individual oils, surfactants 
and co-surfactants. The solubility of Valsartan in various oils is 
determined by adding excess amount of drug in 2 mL of selected 
oils, surfactants and co-surfactants into 5mL vials, and mixed 
thoroughly via vortex mixer [16]. The vials are then kept at 25 °C in 
a shaker for 24 hours. After that, the mixtures were spun using a 
centrifugator (Centrifuge Bench Top Refrigerated, Eppendorf) at 
3000 rpm for 15 minutes. The supernatants were retrieved and 
quantified using UV-Vis spectrophotometer at 251nm [17-18] 
(Lambda 25, Perkin Elmer). 
Pseudo-ternary Phase Diagram 
Based on the individual solubility studies and the hydrophilic-
lipophilic balance (HLB) value, the oil, surfactant and co-surfactant 
are chosen for the construction of the pseudo-ternary phase 
diagram [16]. The surfactant and co-surfactant are mixed in 
different ratio (1:1, 2:1, and 3:1). Phase diagrams are constructed 
for each ratio. For every phase diagram, the proportion of oil and 
Smix varies in different volume ratio from 0:10 to 10:0. The 
percentage of the aqueous phase is determined using aqueous 
titration method [19]. Slow titration of distilled water is added (5% 
addition at a time) into the Smix-oil mixture and the observation of 
the transition from clear to turbid point is noted down. Calculation is 
made to determine the percentage of water, oil and Smix present 
at the point of turbidity. With the obtained individual percentage, a 
pseudo-ternary phase diagram is developed with the clear-solution 
region marked as best emulsification region. The six formulations 
are selected from different region of emulsification area. 
Preparation of Self-nanoemulsifying Drug Delivery 
System 
Aqueous titration was repeated for the selected Smix ratio in the 
presence of valsartan. Another pseudoternary phase diagram was 
constructed in presence of drug as show in Fig.3 and six points 
were randomly picked from the self-nanoemulsifying region. The 
percentage of each component for all six points was calculated and 
presented in Table 1. Correspondingly, six formulations were 
prepared by mixing all specifically measured oil, surfactant, co-
surfactant and 80mg of valsartan. 
Thermodynamic stability testing 
The formulations were subjected to heating-cooling, centrifugation 
and freeze-thaw, where the physical appearances of the 
formulations were observed at the end of each testing. In heating 
cooling, all six formulations were heated at 45°C and then cooled at 
4°C, with the duration of 24 hours at each temperature, for 2 
cycles. Then, formulations which passed the heating-cooling cycles 
were subjected to centrifugation at 3500 rpm for 15 minutes. 
Finally, only formulations which passed the previous two steps 
were stored at alternating temperature of -21°C and 25°C, with the 
duration of 24 hours at each temperature, for 2 cycles. 
Robustness to dilution  
The prepared formulations were diluted infinitely (i.e. 900 times) 
with 4500 μl of water, Phosphate buffer pH 6.80 and acid buffer pH 
1.2 in three separate glass vials. The diluted formulations were 
shaken and then visually inspected after 24 hours for any form of 
instability [16]. 
Droplet size and zeta potential analyses 
This analysis was carried out so as to determine the consistency in 
the size and stability of the emulsion at various dilutions (i.e. 100, 
500 and 900 dilution factors) and dispersant media (miliQ water, 
pH 6.80 PBS and pH 1.20 acid buffer). Malvern Zeta Sizer Nano 
ZS with the conditions of backscatter detection at 173º; 
temperature of 25ºC; refractive index of 1.330 were used. All were 
done in triplicates. 
Transmission Electron Microscopy (TEM) 
A drop of diluted formulation was placed on a carbon-coated 
copper grid, stained with 2% uranyl acetate aqueous solution, and 
examined using the TEM (Philips Tecnai 12). 
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In vitro dissolution studies  
Dissolution studies were carried out using USP Apparatus Type II 
(paddle type) with 900 ml of pH 6.80 ± 0.05 PBS, temperature at 
37 ± 0.5ºC and paddle rotation of 50 rpm. 5 ml of formulation, 
which contained 80 mg of valsartan, was instilled to the dissolution 
medium at time 0 minute. 5 ml of dissolution media was retrieved 
at timed intervals and the amount of valsartan was quantified using 
HPLC method.  
The HPLC analysis is performed using Shimadzu HPLC model LC-
10ADvp, equipped with Shimadzu degasser model DGU-14A; 
system controller SCL-10Avp; fluorescence detector RF-10A XL; 
auto injector SIL-10AD vp; column oven CTO-10AS and 
Prominence Diode Array (PDA) detector SPD-M20A. The 
chromatographic column used was Symmetry Shield RP18 C18 
(250mm × 4.6mm, 5μm particle size) and the mobile phase was 
prepared with ammonium dihydrogen phosphate buffer: methanol 
(2:1) adjusted to pH 3.0 with formic acid.  [17] The solvents used 
are of HPLC grade. Dissolution studies were also done using acid 
buffer pH 1. All were done in triplicates. 
Emulsification time 
Under the same conditions as in vitro dissolution studies, time 
taken by the formulation to form homogenous mixture with the 
dissolution medium was noted in triplicates. The assessment for 
the efficiency of the emulsion system is also made according to the 
following grading system 
Grade A: Rapidly forming emulsion having a clear or bluish 
appearance  
Grade B: Rapidly forming, translucent bluish appearance 
Grade C: Fine milky emulsion forming within 2 minutes 
Grade D: slow forming, slightly oily appearance 
Dispersibility testing 
Under the same conditions as in vitro dissolution studies, the type 
of emulsion formed was visually inspected and categorised as 
either clear, translucent with bluish tone or milky turbid emulsion. 
Accelerated stability testing  
All anhydrous formulations were stored in an incubator at 40ºC and 
75% relative humidity for four weeks. Visual assessment, droplet 
size and zeta potential analyses were conducted for selected 
formulations at the end of the study. 
Result and Discussion 
Solubility studies 
Based on the solubility profile of different oil, surfactant and co-
surfactant  and pre-formulation studies about the interaction 
between drug-excipients as seen in Fig.1., we have selected 
labrasol as oil with 108.9 mg/ml of solubility, Tween 20 as 
surfactant with 47.7mg/ml solubility and  PEG 400 as co-surfactant 
for preparation the SNEDDS formulations. 
As for the selection of Smix, these components must be of GRAS 
status, which suggested safe for oral consumption. The 
combination of oil, surfactant and co-surfactant were ensure to be 
able to solubilise the required amount of drug (80mg at least). 
Besides, another determining factor for the formulation was the 
hydrophilic-lipophilic balance (HLB) value [20]. According to 
William C. Griffin’s method,the desired HLB value to form an oil-in-
water emulsion should be between 8-18[21]. Also, there were 
concerns regarding the solubility of Valsartan in the mixture in 
highly hydrophilic mixture. Upon calculation of selected smix were 
found to have HLB values of approximately 14 which is suitable for 
the preparation oil-in- water type of nanoemulsion that can contain 
80mg of valsartan. 
Construction of pseudo-ternary phase diagram 
On the basis of the solubility of drug, oil, surfactants, co-surfactants 
and aqueous phase were used for construction of phase diagram. 
Oil, surfactant, and co-surfactant are grouped in four different 
combinations for phase studies. Aqueous titration was used for the 
construction of pseudo-ternary phase diagram. The titration was 
done in a way that each aqueous addition with water was 
approximately 5% increment up to 95% [19]. As shown in Fig .2, 
the self-nanoemulsifying regions appeared to increase with 
decreases marginally as increases Smix ratio.  
The Smix 1:1 resulted in the largest self-nanoemulsifying region 
than that of 3:1 as shown in Fig.3. It was also noticeable that 1:1 
ratio of Smix, the mixture can take up greater amount of water and 
still remain as clear mixture with bluish tone during aqueous 
titration. This could be explained by the fact that higher amount of 
surfactants can be adsorbed at the interface and hence, stabilized 
the formation of nanoemulsions. Nanoemulsions appeared 
transparent as their droplet radii fell below the optical wavelength 
of visible light (390 - 750 nm) by which minimum light scattering 
took place and the bluish tone was due to the dominance of low-
wavelength light scattered from them [22]. As the droplet radius 
approached 100 nm, nanoemulsions seemed hazy, and above this, 
in the submicron range, they appeared white due to significant 
multiple light scattering 
The transparency of the emulsion was believed to be inversely 
proportional to the size of the droplets, i.e. the more transparent 
the emulsion is, the smaller the size of the droplets. [23] This is 
because the droplet radii were believed to fall below the optical 
wavelength of visible light with minimal light scattering. However, 
no droplet size analysis was done to confirm the statement above. 
Also, at certain aqueous percentage, appearance of the mixture 
changes for smooth flowing to viscous gel-like appearance, which 
was undefined as an emulsion.  
Formulations of SNEDDS 
No significant (p<0.05) different in self-nanoemulsifying region in 
presence of 80 mg of valsartan and in absence of valsartan was 
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observed as shown in Fig.3. Six points were randomly picked from 
the self-nanoemulsifying region and the formulations were 
summarized in Table 1 
Droplet size analysis 
The droplet size was the main target of the entire formulation of 
study, where it was postulated that the smaller the droplet size, the 
larger the interfacial area, thus the greater the partitioning of the 
drug across the gastrointestinal lining. The droplet size of all the 
formulations were examined at different dilutions, i.e. 100, 500 and 
900 times dilution with water and the results are presented in Table 
2. The purpose was clear, which is to detect any changes in droplet 
size with the increasing dilutions. However, there was no 
consensus on the exact size range of nanoemulsion. In the present 
study, average droplet size of formulation F1 and F2 were found to 
be less than 200 nm with low polydispersity index (<0.5) as shown 
Table 2.  The result would show a clear picture regarding \stability 
behaviour of the emulsion within the gastrointestinal tract, where 
the consistency in the emulsion droplet size was observed.  
Effect of droplet size and zeta potential in different 
dispersant media  
Due to considerable pH variations along gastrointestinal tracts, it is 
rational to observe the consequence of different media on the 
SNEDDS. Although the droplet sizes of  the formulations were 
found to be less than 200nm  with low polydispersity index (<5) as 
shown in Table 3. 
The droplet size of formulations changes marginally at different 
dispersant media (Table 3). The droplet size is increases when it 
disperses in acid buffer pH1.2 as compared to water PBS pH6.8 as 
seen in Table 3. This may be due to the weakly acidic valsartan, 
which was mainly unionised at lower pH, which remained in the oil 
droplets and hence resulting in bigger droplet size at acidic 
condition. As opposed, the weakly acidic valsartan was mainly 
ionised at higher pH, had the tendency to diffuse to the continuous 
phase of PBS, resulting in smaller droplet size at basic condition 
[23]. The physical stability of the emulsions can be projected 
through the zeta potential analysis. Zeta potential is an indication of 
the degree of repulsion between the individual droplets in the entire 
emulsion. The zeta potential of formulation was found to be in the 
range between +3.98 to -19.45 which would be better the stability 
of the emulsion as the individual droplets repels each another to 
coalescence into larger globules [24-25].  
Transmission Electron Microscopy (TEM) 
Microscopy analysis revealed well-defined circular globules with 
the size of less than  100 nm as shown in figure 4. The TEM photo 
graph indicated that the formed O/W nanoemulsion globules has 
smooth surface with no surface drug crystals. 
 
Robustness to dilution/precipitation 
The dilution capability of the formulations was tested to determine 
the capability of the formulation to withstand possibly infinite 
dilutions. This was because upon ingestion, the gastrointestinal 
fluids are responsible for the dilution, and it is impossible to 
accurately identify the amount of water present to form emulsion 
with the formulation Robustness to dilution was performed diluted 
with excess of water, standard phosphate buffer pH 6.8 and 0.1N 
HCl (500-900 ml) and was stored for 12 hours and result were 
indicated that there was no precipitation or phase separation as 
shown in Table 4.The ability of SNEDDS formulation to withstand 
aqueous dilution was found to be fascinating. The phenomenon 
was attributed to the high solubilising properties of the excipients, 
and also the capability to form a relatively stable emulsion with 
small droplet sizes [24].  This implied that these formulations were 
stable at infinite water dilution. 
In- vitro dissolution studies  
The in-vitro dissolution studies of formulations (F1 & F2), Diavon 
tablet and Valsartn drug powder were performed in acidic buffer pH 
1.2. The dissolution profiles of formulations were compared with 
marketed tablet (Diovan tablet) and valsartan drug powder and 
results are shown in fig 5 and 6. 
The maximum drug release from formulation F1 and F2 were found 
to be 86.12 % and 86.46% , respectively at end of 40 min, whereas 
the maximum drug release from marketed valsartan tablet and 
valsartan powder were found to be 14.36% and 7.45%, 
respectively at end of 40 min. The results from figure 5 and 6 is 
clearly indicates that rate and extent of dissolution of prepared 
formulations (F1 and F2) were significantly (p<0.05) higher than 
that of marketed valsartan tablet and valsartan powder. 
It could be suggested that the SNEDDS formulation resulted in 
spontaneous formation of a nanoemulsion with a small droplet size, 
which permitted a faster rate of drug release into the aqueous 
phase, significantly much faster than that of marketed valsartan 
tablet and powder.  
Thermodynamic stability testing 
The thermodynamic results of the formulation in shown in Table 5. 
All of SNEDDS formulations were passed the thermodynamic 
stability testing as there was no sign of phase separation or drug 
precipitation at the end of all cycles 
. This suggested that the formulations were robust against storage 
at extreme conditions. 
Emulsification time 
The most of the prepared SNEDDS formulations were formed the 
nanoemulsion in less than 1 min with grade A and B as shown in 
Table 6.  The formulation F1 and F2 were formed the 
nanoemulsion within 30 seconds with grade A system in PBS and  
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Fig.1. Saturation solubility valsartan in different oil, surfactants and Co-surfactants 
  
Fig.2. Pseudoternary phase diagrams of Labrasol, Tween 20 and PEG 400 (Smix) and water, in the absence of valsartan, with 
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Fig.3. Pseudoternary phase diagrams of Labrasol, Tween 20 and PEG 400 (Smix) and water in the presence of 80mg of 
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powder and results are shown in fig 5 and 6 
.  
Fig.5. In vitro dissolution profile of formulation F1 as compared with Diavon tablet and valsartan powder using acid buffer pH 1.2. 
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Table.1. Percentage of each component in the selected six formulations. 
Formulation Labrasol  (% v/v) Tween 20 (% v/v)  PEG 400HP  (% v/v) 
F1 50.5 25.0 25.0 
F2 67.0 16.5 16.5 
F3 50.0 37.5 15.5 
F4 40.5 48.5 16.0 
F5 25.0 25.0 19.0 
F6 45.5 42.5 20.5 
 
Table.2. The average droplet size of all six formulations at various dilution factors with water (n=3). 
Formulation Dilution factor Droplet size (nm) PDI 
F1 100 94.41 ± 1.45 0.421 ± 0.024 
F1 500 89.47 ± 0.98 0.345 ± 0.016 
F1 900 84.15 ± 1.14 0.368 ± 0.031 
F2 100 114.47 ± 1.45 0.347 ± 0.005 
F2 500 106.45 ± 2.45 0.381 ± 0.089 



























Formulation Dispersant media 
Droplet size 
(nm) PDI Zeta potential (mV) 
F1 Water 94.41 ± 1.65 0.345± 0.044 -18.45 ± 0.46 
F1 Acid buffer  pH 1.2 117.14 ± 1.45 0.341 ± 0.033 -10.45 ± 0.21 
F1 PBS pH 6.8 114.63 ± 2.45 0.421 ± 0.014 15.17 ± 0.47 
F2 Water 108.47 ± 1.45 0.347 ± 0.005 -16.90 ± 1.57 
F2 Acid buffer  pH 1.2 122.85 ± 2.24 0.526 ± 0.017 -12.80 ± 1.11 
F2 PBS pH 6.8 101.21 ± 1.41 0.557 ± 0.045 3.98 ± 0.71 
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Table.4. Robustness to dilution of formulation in different dissolution medium.  
Dissolution medium F1 F2 F3 F4 F5 F6 
Water P P P P P P 
Acid buffer pH 1.2 P P P P F P 
Phosphate buffer pH 6.8 P P P P P P 
P = Passed, F= Failed 
Table.5. Thermodynamic stability studies of SNEDDS formulation under different stability conditions  
Formulations Heating cooling cycle Centrifugation Freeze thaw cycle 
F1 P P P 
F2 P P P 
F3 P P P 
F4 P P F 
F5 F P P 
F6 P P P 
  P = Passed, F= Failed 
 
Table.6. Assessment of self- emulsification parameters of formulation in dissolution medium.  
Formulations Self-emulsification time (Seconds) 
 
Assessment of self-emulsification 
F1 
18.45 ± 1.74 Grade A 
F2 
13.45 ± 1.34 Grade A 
F3 
28.12 ± 1.44 Grade B 
F4 
36.45 ± 1.82 Grade D 
F5 
42.45 ± 1.46 Grade D 
F6 





Table.7. The droplet size, PDI and zeta potential of formulation F1 and F2 before and after accelerated stability study (n=3). 
 
Before accelerated stability study After accelerated stability study 
Batch Droplet size 
(nm) 




PDI Zeta potential 
(mV) 
 
F1 94.41 ± 1.65 0.345± 0.044 -18.45 ± 0.46 98.42± 1.28 0.328 ± 0.12 -19.45 ± 0.28 
 
F2 108.47 ± 1.45 0.347 ± 0.005 -16.90 ± 1.57 
119.10± .94 
 
0.347 ± 0.02 
 
-16.44 ± 1.87 
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acid buffer. The results are indicating that the prepared SNEDDS 
formulations form a good and stable nanoemulsion in different 
dissolution with short time duration (<1 min).  
The accelerate stability test was performed at 45°C/75RH for 
8weeks. There was no observation of phase separation, drug 
precipitation or colour change in formulations F1 and F2 at the end 
of 8-weeks accelerated stability conditions. Particle size and Zeta 
potential measurement also revealed similar droplet size (p>0.05) 
and relatively stable droplets as shown in Table 7. 
Conclusion 
The SNEDDS containing valsartan was successfully prepared 
using Labrasol (oil) Tween 20 (surfactant) and PEG 400 (co-
surfactant). The prepared formulations were formed nanoemulsion 
in different pH conditions with particle size~100nm. Furthermore, 
the results are indicated that the prepared formulations are having 
a good stability in the terms of droplet size, zeta potential under 
different dispersant media and stability conditions. This formulation 
showed significant improvement in rate of dissolution of valsartan 
in acidic buffer pH1.20 which is more than 6-fold of drug release as 
compared to marketed valsartan tablet. Thus, this greater 
dissolution of valsartan from the SNEDDS formulation could lead to 
higher absorption and higher oral bioavailability. 
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